Everything You Need to Know About the FDA Peptide Ban FDA Compliance for Peptide Therapy and BPC 157 Holt Law FDA moves toward easing restrictions on certain peptides BioPharma Dive In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and